These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 15872078

  • 1. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.
    J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
    [Abstract] [Full Text] [Related]

  • 2. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 3. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar 14; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 4. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
    Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S, RENAAL Study Investigators.
    J Renin Angiotensin Aldosterone Syst; 2000 Dec 14; 1(4):328-35. PubMed ID: 11967819
    [Abstract] [Full Text] [Related]

  • 5. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec 14; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 6. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun 14; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 7. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 8. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
    J Am Soc Nephrol; 2007 May 01; 18(5):1540-6. PubMed ID: 17409317
    [Abstract] [Full Text] [Related]

  • 9. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.
    Diabetes Care; 2008 Mar 01; 31(3):445-7. PubMed ID: 18070995
    [Abstract] [Full Text] [Related]

  • 10. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Circulation; 2004 Aug 24; 110(8):921-7. PubMed ID: 15302780
    [Abstract] [Full Text] [Related]

  • 11. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM, RENAAL Investigators.
    Kidney Int Suppl; 2002 Dec 24; (82):S64-7. PubMed ID: 12410858
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.
    Diabetes Care; 2006 Oct 24; 29(10):2210-7. PubMed ID: 17003295
    [Abstract] [Full Text] [Related]

  • 13. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005 Oct 24; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 14. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group.
    J Am Soc Nephrol; 2004 Dec 24; 15(12):3117-25. PubMed ID: 15579515
    [Abstract] [Full Text] [Related]

  • 15. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.
    Kidney Int Suppl; 2002 Dec 24; (82):S68-72. PubMed ID: 12410859
    [Abstract] [Full Text] [Related]

  • 16. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 17. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 01; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S, Noshad H, Tabrizi A, Mobasseri M, Tayebi Khosroshahi H, Heydarnejad M, Khalaj MR, Aghamohammadzadeh N.
    Iran J Kidney Dis; 2012 Jan 01; 6(1):39-43. PubMed ID: 22218118
    [Abstract] [Full Text] [Related]

  • 19. Losartan and end-organ protection--lessons from the RENAAL study.
    Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM, RENAAL Investigators.
    Clin Cardiol; 2005 Mar 01; 28(3):136-42. PubMed ID: 15813620
    [Abstract] [Full Text] [Related]

  • 20. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.
    Am J Kidney Dis; 2012 Jan 01; 59(1):75-83. PubMed ID: 22051245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.